Banana Boat, actress Busy Philipps launch summer sweepstakes
SHELTON, Conn. — Energizer Personal Care, the makers of Banana Boat sunscreen, along with actress Busy Philipps, announced on Thursday the launch of the Best Summer Ever Sweepstakes.
The Banana Boat Best Summer Ever Sweepstakes gives families the chance to spin the Wheel of Fun, hosted on the Banana Boat Facebook fan page, for a chance to win daily prizes, including gift cards, Banana Boat brand gift baskets, movie passes for four and a family fun prize pack. Each spin also automatically enters participants into a sweepstakes for a chance to win the grand prize family trip to a Treesort — a tree house resort adventure.
Banana Boat also is equipping families to have the Best Summer Ever through its offering of four new sunscreens:
- Banana Boat Triple Defense Sunscreen for Men Lotion and Clear UltraMist: A full line of sunscreens designed specifically for men that contains ActiveProtect Technology, provides heavy-duty sun protection, hydrates skin and combats odor;
- Banana Boat Kids Free Clear UltraMist Sunscreen: An alcohol-free, tear-free, sting-free kids clear spray;
- Banana Boat Sport Performance Clear UltraMist Sunscreen with Powerstay Technology: Specifically designed for the sport enthusiast and active individual who doesn’t want to be slowed down while out in the sun; and
- Banana Boat Protect & HydrateTM Sunscreen Clear UltraMist: A 2-in-1 combination of sunscreen and all-day moisturizer.
Mylan launches generic version of GlaxoSmithKline’s Malarone tablets
PITTSBURGH — Mylan on Thursday announced that it has launched atovaquone and proguanil hydrochloride tablets, 62.5 mg/25 mg and 250 mg/100 mg, the generic version of GlaxoSmithKline’s Malarone tablets.
Mylan received final approval from the Food and Drug Administration for its abbreviated new drug application for this product, which is indicated to prevent Plasmodium falciparum malaria and the treatment of acute, uncomplicated P. falciparum malaria.
Atovaquone and proguanil hydrochloride tablets, 62.5 mg/25 mg and 250 mg/100 mg, had U.S. sales of approximately $89.4 million for the 12 months ended March 31, 2014, Mylan reported, citing IMS Health.
High blood pressure drugs may be associated with increased risk of vision-threatening disease
SAN FRANCISCO — There may be a connection between taking vasodilators and developing early-stage, age-related macular degeneration, the leading cause of vision loss and blindness among Americans who are ages 65 and older, according to a study published online Wednesday in Ophthalmology, the journal of the American Academy of Ophthalmology.
AMD — the deterioration of the eye’s macula, which is responsible for the ability to see fine details clearly — affects an estimated 11 million people in the United States. In addition to increased age, the cause of AMD may be attributed to several risk factors, including hereditary risk and smoking. Some studies also have found an association between AMD and high blood pressure, but this has been inconsistent. To help clarify the relationship between AMD incidence and blood pressure-lowering medications, including vasodilators, researchers from the University of Wisconsin School of Medicine and Public Health conducted a long-term population-based cohort study from 1988 to 2013 of nearly 5,000 residents of Beaver Dam, Wis., ages 43 years to 86 years. The research is part of the National Eye Institute-funded Beaver Dam Eye Study, which has collected information on the prevalence and incidence of AMD, macular degeneration and diabetic retinopathy since 1987.
The researchers found that — after adjusting for age, sex and other factors — using any vasodilator, which open (dilate) the blood vessels, was associated with a 72% greater risk of developing early-stage AMD. Among people who were not taking vasodilators, an estimated 8.2% developed signs of early AMD. In comparison, among those taking a vasodilator medication, 19.1% developed the disease.
The researchers also found that taking oral beta blockers was associated with a 71% increase in the risk of neovascular AMD, a more advanced and vision-threatening form of the disease. Among those who were not taking oral beta blockers, an estimated 0.5% developed signs of neovascular AMD. In comparison among those taking oral beta blockers, 1.2% developed neovascular AMD.
While the study provides risk estimates of associations between blood pressure-lowering medications and AMD at various stages, the researchers caution that their study was not able to discern effects of the medications themselves and the conditions for which participants were taking those medications.
"As significant as these results may be, it’s important that they be replicated first, and if possible tested in a clinical trials setting before changing anyone’s medication regimens," said Ronald Klein, lead researcher of the study. "Further research is needed to determine the cause of these increased risks."